Skip to main content

Table 1 Patient characteristics (ITT population)

From: S-1 combined with docetaxel following doxorubicin plus cyclophosphamide as neoadjuvant therapy in breast cancer: phase II trial

Characteristics

n

(%)

Number of total patients

49

 

Median age, years (range)

43 (27–60)

Menopausal status

  

   Premenopause

42

(85.7%)

   Postmenopause

7

(14.3%)

Histology

  

   Invasive ductal carcinoma

46

(93.9%)

   Invasive lobular carcinoma

1

(2.0%)

   Mixed type (ductal + lobular)

2

(4.1%)

ECOG performance status

  

   0

25

(51.0%)

   1

24

(49.0%)

Prechemotherapy T stage

  

   cT1

5

(10.3%)

   cT2

37

(75.5%)

   cT3

6

(12.2%)

   cT4

1

(2.0%)

Prechemotherapy N stage

  

   cN0

0

(0.0%)

   cN1

30

(61.2%)

   cN2

14

(28.6%)

   cN3

5

(10.2%)

AJCC clinical stage

  

   IIA

3

(6.1%)

   IIB

25

(51.0%)

   IIIA

16

(32.7%)

   IIIB

0

(0.0%)

   IIIC

5

(10.2%)

Median tumor size by palpation, cm (range)

4.0 (0–11.0)

Hormonal receptor status*

  

   Positive for ER or PgR

36

(73.5%)

   Negative for ER and PgR

13

(26.5%)

HER2 status

  

   Positive

0

(0.0%)

   Negative

49

(100%)

  1. ECOG, Eastern Cooperative Oncology Group; ER, estrogen receptor; PgR, progesterone receptor. *The cut-off of ER and PgR positivity was 10% stained cells by immunohistochemistry.